Sundance Biosciences, SUN-627, TYK2 Inhibitor, Multiple Sclerosis, Progressive MS, Phase 1 Clinical Trial, Neuroinflammation, CNS Penetration, Immunology,

SOUTH SAN FRANCISCO, Calif. — October 21, 2026 Sundance Biosciences, a clinical-stage biotechnology company developing next-generation tyrosine kinase 2...